BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 19752333)

  • 1. Cost effectiveness and screening interval of lipid screening in Hodgkin's lymphoma survivors.
    Chen AB; Punglia RS; Kuntz KM; Mauch PM; Ng AK
    J Clin Oncol; 2009 Nov; 27(32):5383-9. PubMed ID: 19752333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computed tomography screening for lung cancer in Hodgkin's lymphoma survivors: decision analysis and cost-effectiveness analysis.
    Das P; Ng AK; Earle CC; Mauch PM; Kuntz KM
    Ann Oncol; 2006 May; 17(5):785-93. PubMed ID: 16500905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose chest computed tomography for lung cancer screening among Hodgkin lymphoma survivors: a cost-effectiveness analysis.
    Wattson DA; Hunink MG; DiPiro PJ; Das P; Hodgson DC; Mauch PM; Ng AK
    Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):344-53. PubMed ID: 25104066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease.
    Guadagnolo BA; Punglia RS; Kuntz KM; Mauch PM; Ng AK
    J Clin Oncol; 2006 Sep; 24(25):4116-22. PubMed ID: 16943528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia.
    Blake GJ; Ridker PM; Kuntz KM
    Am J Med; 2003 Apr; 114(6):485-94. PubMed ID: 12727581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men.
    Goldie SJ; Kuntz KM; Weinstein MC; Freedberg KA; Welton ML; Palefsky JM
    JAMA; 1999 May; 281(19):1822-9. PubMed ID: 10340370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health Benefits and Cost-Effectiveness of Children's Oncology Group Breast Cancer Screening Guidelines for Chest-Irradiated Hodgkin Lymphoma Survivors.
    Wong FL; Lee JM; Leisenring WM; Neglia JP; Howell RM; Smith SA; Oeffinger KC; Moskowitz CS; Henderson TO; Mertens A; Nathan PC; Yasui Y; Landier W; Armstrong GT; Robison LL; Bhatia S
    J Clin Oncol; 2023 Feb; 41(5):1046-1058. PubMed ID: 36265088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of screening for anal squamous intraepithelial lesions and anal cancer in human immunodeficiency virus-negative homosexual and bisexual men.
    Goldie SJ; Kuntz KM; Weinstein MC; Freedberg KA; Palefsky JM
    Am J Med; 2000 Jun; 108(8):634-41. PubMed ID: 10856411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.
    Manser R; Dalton A; Carter R; Byrnes G; Elwood M; Campbell DA
    Lung Cancer; 2005 May; 48(2):171-85. PubMed ID: 15829317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis for HbA1c test intervals to screen patients with type 2 diabetes based on risk stratification.
    Ohde S; Moriwaki K; Takahashi O
    BMC Endocr Disord; 2021 May; 21(1):105. PubMed ID: 34022872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: Many happy returns on investment?
    Ademi Z; Norman R; Pang J; Liew D; Zoungas S; Sijbrands E; Ference BA; Wiegman A; Watts GF
    Atherosclerosis; 2020 Jul; 304():1-8. PubMed ID: 32526542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-utility analysis of orthoptic screening in kindergarten: a Markov model based on data from Germany.
    König HH; Barry JC
    Pediatrics; 2004 Feb; 113(2):e95-108. PubMed ID: 14754978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An economic evaluation of an abdominal aortic aneurysm screening program in Italy.
    Giardina S; Pane B; Spinella G; Cafueri G; Corbo M; Brasseur P; Orengo G; Palombo D
    J Vasc Surg; 2011 Oct; 54(4):938-46. PubMed ID: 21820837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma.
    Delea TE; Sharma A; Grossman A; Eichten C; Fenton K; Josephson N; Richhariya A; Moskowitz AJ
    J Med Econ; 2019 Feb; 22(2):117-130. PubMed ID: 30375910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis.
    Inadomi JM; Sampliner R; Lagergren J; Lieberman D; Fendrick AM; Vakil N
    Ann Intern Med; 2003 Feb; 138(3):176-86. PubMed ID: 12558356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma.
    Fust K; Li X; Maschio M; Villa G; Parthan A; Barron R; Weinstein MC; Somers L; Hoefkens C; Lyman GH
    Pharmacoeconomics; 2017 Apr; 35(4):425-438. PubMed ID: 27928760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of screening for colorectal cancer in the general population.
    Frazier AL; Colditz GA; Fuchs CS; Kuntz KM
    JAMA; 2000 Oct; 284(15):1954-61. PubMed ID: 11035892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Newborn screening by tandem mass spectrometry for medium-chain Acyl-CoA dehydrogenase deficiency: a cost-effectiveness analysis.
    Venditti LN; Venditti CP; Berry GT; Kaplan PB; Kaye EM; Glick H; Stanley CA
    Pediatrics; 2003 Nov; 112(5):1005-15. PubMed ID: 14595039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease.
    Fonarow GC; Keech AC; Pedersen TR; Giugliano RP; Sever PS; Lindgren P; van Hout B; Villa G; Qian Y; Somaratne R; Sabatine MS
    JAMA Cardiol; 2017 Oct; 2(10):1069-1078. PubMed ID: 28832867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.